Skip to main content
SpringerLink
Log in

LNH cérébral

  • Chapter
Tumeurs malignes rares

  • 64 Accesses

Résumé

Les lymphomes cérébraux primitifs (LCP) représentent 1–2% des lymphomes malins non hodgkiniens (LNH) et environ 5% des tumeurs cérébrales. Plusieurs études montrent une augmentation de l’incidence des LCP notamment aux États-Unis, au Royaume-Uni, aux Pays-Bas, en Norvège tandis qu’elle semble rester stable au Canada, au Danemark, en Écosse, à Hong Kong (1, 2). L’incidence annuelle est estimée entre 2 et 5 par million dans ces différents pays. Le risque relatif de LCP est multiplié par plus de 3500 en cas d’immunodépression non contrôlée pour les patients infectés par le VIH et chez les patients ayant bénéficié d’une transplantation d’organe et recevant une immunosuppression (3). On observe également une augmentation progressive de l’incidence des LCP chez les transplantés d’organe qui ne semble pas seulement expliquée par l’augmentation du nombre de greffes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Haldorsen IS, Krossnes BK, Aarseth JH, et al. (2007) Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989–2003: time trends in a 15-year national survey. Cancer 110: 1803–14

    Article  PubMed  Google Scholar 

  2. Kadan-Lottick NS, Skluzacek MC, Gurney JG (2002) Decreasing incidence rates of primary central nervous system lymphoma. Cancer 95: 193–202

    Article  PubMed  Google Scholar 

  3. Cote TR, Manns A, Hardy CR, et al. (1996) Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst 88: 675–9

    Article  CAS  PubMed  Google Scholar 

  4. Bataille B, Delwail V, Menet E, et al. (2000) Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 92: 261–6

    Article  CAS  PubMed  Google Scholar 

  5. Abrey LE, Ben Porat L, Panageas KS, et al. (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24: 5711–5

    Article  PubMed  Google Scholar 

  6. Ferreri AJ, Blay JY, Reni M, et al. (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21: 266–72

    Article  PubMed  Google Scholar 

  7. Ghesquières H, Sunyach MP, Drouet Y, et al. (2008) Long-Term Follow-Up of 132 Immunocompetent Primary Central Nervous System Lymphomas Treated at Leon Berard Cancer Centre: Proposition of a New Prognostic Model. Blood 110, Abstract 521

    Google Scholar 

  8. Abrey LE, Batchelor TT, Ferreri AJ, et al. (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23: 5034–43

    Article  PubMed  Google Scholar 

  9. Mohile NA, DeAngelis LM, Abrey LE (2008) The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol

    Google Scholar 

  10. Gaidano G, Capello D, Pastore C, et al. (1997) Analysis of human herpesvirus type 8 infection in AIDS-related and AIDS-unrelated primary central nervous system lymphoma. J Infect Dis 175: 1193–7

    Article  CAS  PubMed  Google Scholar 

  11. Shenkier TN, Blay JY, O’Neill BP, et al. (2005) Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 23: 2233–9

    Article  PubMed  Google Scholar 

  12. Spectre G, Gural A, Amir G, et al. (2005) Central nervous system involvement in indolent lymphomas. Ann Oncol 16: 450–4

    Article  CAS  PubMed  Google Scholar 

  13. Camilleri-Broet S, Criniere E, Broet P, et al. (2006) A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 107: 190–6

    Article  CAS  PubMed  Google Scholar 

  14. Krumbholz M, Theil D, Derfuss T, et al. (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201: 195–200

    Article  CAS  PubMed  Google Scholar 

  15. Ponzoni M, Berger F, Chassagne-Clement C, et al. (2007) Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br J Haematol 138: 316–23

    Article  CAS  PubMed  Google Scholar 

  16. Ferreri AJ, Foppoli M, Martelli M et al. (2008) Randomized phase II trial of primary chemotherapy with high dose methotrexate alone or associated with high dose cytarabine for patients with primary CNS lymphomas. Ann Oncol 19, Abstract 65

    Google Scholar 

  17. Nelson DF, Martz KL, Bonner H, et al. (1992) Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23: 9–17

    Article  CAS  PubMed  Google Scholar 

  18. Mead GM, Bleehen NM, Gregor A, et al. (2000) A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 89: 1359–70

    Article  CAS  PubMed  Google Scholar 

  19. Blay JY, Conroy T, Chevreau C, et al. (1998) High-dose methotrexate for the treatment of primary cerebral lym phomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16: 864–71

    CAS  PubMed  Google Scholar 

  20. Bessell EM, Lopez-Guillermo A, Villa S, et al. (2002) Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 20: 231–6

    Article  CAS  PubMed  Google Scholar 

  21. DeAngelis LM, Seiferheld W, Schold SC, et al. (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93–10. J Clin Oncol 20: 4643–8

    Article  Google Scholar 

  22. Ferreri AJ, Dell’Oro S, Foppoli M, et al. (2006) MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 66: 1435–8

    Article  CAS  PubMed  Google Scholar 

  23. Gavrilovic IT, Hormigo A, Yahalom J, et al. (2006) Longterm follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24: 4570–4

    Article  CAS  PubMed  Google Scholar 

  24. Kiewe P, Fischer L, Martus P, et al. (2008) Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis. Cancer 112: 1812–20

    Article  PubMed  Google Scholar 

  25. O’Brien P, Roos D, Pratt G, et al. (2000) Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18: 519–26

    PubMed  Google Scholar 

  26. Omuro AM, DeAngelis LM, Yahalom J, Abrey LE (2005) Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with compleète follow-up. Neurology 64: 69–74

    Article  CAS  PubMed  Google Scholar 

  27. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. (2003) High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDSrelated primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21: 4483–8

    Article  CAS  PubMed  Google Scholar 

  28. Desablens B, Gardembas M, Haie-Meder C, et al. (1999) Primary central nervous system lymphoma: long term results of the GOELAMS LCP 88 trial with a focus on neurological complications among 152 patients. Ann Oncol 10, suppl 3, Abstract 40

    Google Scholar 

  29. Ghesquières H, Ferlay C, Sebban C, et al. (2008) Longterm follow-up of the C5R protocol of high dose chemotherapy and radiotherapy in 100 newly diagnosed primary CNS lymphoma: a prospective multicentric phase II study of the GELA. Ann Oncol 19, suppl 4, Abstract 40

    Google Scholar 

  30. Correa DD, Maron L, Harder H, et al. (2007) Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 18: 1145–51

    Article  CAS  PubMed  Google Scholar 

  31. Reni M, Ferreri AJ, Guha-Thakurta N, et al. (2001) Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys 51: 419–5

    Article  CAS  PubMed  Google Scholar 

  32. Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18: 3144–50

    CAS  PubMed  Google Scholar 

  33. Freilich RJ, Delattre JY, Monjour A, DeAngelis LM (1996) Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46: 435–9

    CAS  PubMed  Google Scholar 

  34. Herrlinger U, Kuker W, Uhl M, et al. (2005) NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57: 843–7

    Article  CAS  PubMed  Google Scholar 

  35. Hoang-Xuan K, Taillandier L, Chinot O, et al. (2003) Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21: 2726–31

    Article  CAS  PubMed  Google Scholar 

  36. McAllister LD, Doolittle ND, Guastadisegni PE, et al. (2000) Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery. 46: 51–60

    Article  CAS  PubMed  Google Scholar 

  37. Ng S, Rosenthal MA, Ashley D, Cher L (2000) High-dose methotrexate for primary CNS lymphoma in the elderly. Neuro Oncol 2: 40–4

    CAS  PubMed  Google Scholar 

  38. Omuro AM, Taillandier L, Chinot O, et al. (2007 ) Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 85: 207–11

    Article  CAS  PubMed  Google Scholar 

  39. Pels H, Schmidt-Wolf IG, Glasmacher A, et al. (2003) Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21: 4489–95

    Article  CAS  PubMed  Google Scholar 

  40. Neuwelt EA, Goldman DL, Dahlborg SA, et al. (1991) Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 9: 1580–90

    CAS  PubMed  Google Scholar 

  41. Sandor V, Stark-Vancs V, Pearson D, et al. (1998) Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16: 3000–6

    CAS  PubMed  Google Scholar 

  42. Guha-Thakurta N, Damek D, Pollack C, Hochberg FH (1999) Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43: 259–68

    Article  CAS  PubMed  Google Scholar 

  43. Gerstner ER, Carson KA, Grossman SA, Batchelor TT (2008) Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology 70: 401–2

    Article  PubMed  Google Scholar 

  44. Khan RB, Shi W, Thaler HT, et al. (2002) Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 58: 175–8

    Article  PubMed  Google Scholar 

  45. Ferreri AJ, Reni M, Pasini F, et al. (2002) A multicenter study of treatment of primary CNS lymphoma. Neurology 58: 1513–20

    CAS  PubMed  Google Scholar 

  46. Soussain C, Hoang-Xuan K, Taillandier L, et al. (2008) Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 26: 2512–8

    Article  PubMed  Google Scholar 

  47. Plotkin SR, Betensky RA, Hochberg FH, et al. (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 10: 5643–6

    Article  CAS  PubMed  Google Scholar 

  48. Nguyen PL, Chakravarti A, Finkelstein DM, et al. (2005) Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 23: 1507–13

    Article  PubMed  Google Scholar 

  49. Reni M, Zaja F, Mason W, et al. (2007) Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 96: 864–7

    Article  CAS  PubMed  Google Scholar 

  50. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63: 901–3

    CAS  PubMed  Google Scholar 

  51. Voloschin AD, Betensky R, Wen PY, et al. (2008) Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 86: 211–5

    Article  CAS  PubMed  Google Scholar 

  52. Iwamoto FM, Schwartz J, Pandit-Taskar N, et al. (2007) Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer 110: 2528–34

    Article  CAS  PubMed  Google Scholar 

  53. Shah GD, Yahalom J, Correa DD, et al. (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25: 4730–5

    Article  CAS  PubMed  Google Scholar 

  54. Rubenstein JL, Fridlyand J, Abrey L, et al. (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25: 1350–6

    Article  CAS  PubMed  Google Scholar 

  55. Shenkier TN, Voss N, Chhanabhai M, et al. (2005) The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency. Cancer 103: 1008–17

    Article  PubMed  Google Scholar 

  56. Panageas KS, Elkin EB, DeAngelis LM, et al. (2005) Trends in survival from primary central nervous system lymphoma, 1975–1999: a population-based analysis. Cancer 104: 2466–72

    Article  PubMed  Google Scholar 

  57. Shibamoto Y, Tsuchida E, Seki K, et al. (2004) Primary central nervous system lymphoma in Japan 1995–1999: changes from the preceding 10 years. J Cancer Res Clin Oncol 130: 351–6

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’hématologie Département d’oncologie-médicale, Centre Léon-Bérard, 28, rue Laënnec, 69373, Lyon

    Hervé Ghesquières

  2. Département de cancérologie médicale Équipe Cytokines et Cancer Unité INSERM 590 Conticanet Network of Excellence FP6-018806 Service d’oncologie médicale, pavillon E, Hôpital Edouard-Herriot, Place d’Arsonval, 69437, Lyon Cedex 03

    Jean -Yves Blay

  3. Centre Léon-Bérard, Université Claude-Bernard-Lyon I, 28, rue Laënnec, 69008, Lyon

    Jean -Yves Blay

Authors
  1. Hervé Ghesquières
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean -Yves Blay
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Ghesquières, H., Blay, J.Y. (2010). LNH cérébral. In: Tumeurs malignes rares. Springer, Paris. https://doi.org/10.1007/978-2-287-72070-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-72070-3_8

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-72069-7

  • Online ISBN: 978-2-287-72070-3

Publish with us

Policies and ethics

Search

Navigation